Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in resected esophageal or gastroesophageal junction cancer
NCT02743494Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2016
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial in esophageal cancer and gastroesophageal junction cancer comparing Nivolumab with Placebo (2 arms). Primary endpoint: Disease-Free Survival at 46 months. Started Jul 2016; status: completed.
02
Drugs
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT02743494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743494.